China

Brii Bio shelves once-promising COVID antibody combo that stood up to variants
Brii Bio shelves once-promising COVID antibody combo that stood up to variants
Fierce Pharma
Brii Biosciences
COVID-19
BRII-196/198
China
FDA
Flag link:
GE HealthCare forms Chinese joint venture to sell non-premium imaging systems
GE HealthCare forms Chinese joint venture to sell non-premium imaging systems
Medtech Dive
GE Healthcare
China
imaging
Medtech
Flag link:
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Fierce Biotech
Junshi Biosciences
Amgen
Sanofi
China
clinical trials
PCSK9 inhibitors
Flag link:
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
BioSpace
Clover BioPharmaceuticals
China
COVID-19
vaccines
boosters
Flag link:
Davos 2023: Moderna CEO in talks with China to supply COVID vaccines
Davos 2023: Moderna CEO in talks with China to supply COVID vaccines
Reuters
Moderna Therapeutics
Stephane Bancel
Pharma CEOs
China
COVID-19
vaccines
Flag link:
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Fierce Pharma
AbbVie
Novartis
China
drug pricing
Pfizer
Paxlovid
Flag link:
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
Pharmaphorum
Luye Pharma
China
FDA
schizophrenia
Rykindo
Flag link:
Sorrento reports positive data from oral Covid-19 treatment trial
Sorrento reports positive data from oral Covid-19 treatment trial
Clinical Trials Arena
Sorrento Therapeutics
clinical trials
ovydso
COVID-19
China
Flag link:
Cancer Drug Supplier’s IPO Mints China’s Latest Billionaire
Cancer Drug Supplier’s IPO Mints China’s Latest Billionaire
Forbes
China
Sichuan Biokin Pharmaceutical
Flag link:
US puts hold on F-star's takeover by China’s Sino Biopharm, citing national security risks
US puts hold on F-star's takeover by China’s Sino Biopharm, citing national security risks
Endpoints
China
M&A
F-star Therapeutics
Sino Biopharmaceutical
Flag link:
U.S. imposes Covid testing requirements on travelers from China
U.S. imposes Covid testing requirements on travelers from China
Stat
China
COVID-19
Public Health
Flag link:
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
Merck
China
Kelun-Biotech
antibody-drug conjugate
oncology
Flag link:
Boston Scientific to Take Majority Stake in Chinese Medtech Company
Boston Scientific to Take Majority Stake in Chinese Medtech Company
Medical Devices and Diagnostics Industry
Medtech
devices
Boston Scientific
China
Acotec
M&A
Flag link:
Chinese market recovery could spur international medtech growth in 2023: Goldman
Chinese market recovery could spur international medtech growth in 2023: Goldman
Medtech Dive
China
Medtech
devices
Flag link:
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug
Fierce Pharma
Eli Lilly
Innovent Biologics
Tyvyt
China
Flag link:
CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit
CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit
Fierce Pharma
China
Pharma CEOs
Bayer
Merck KGaA
BioNTech
Flag link:
FDA again delays review of Amicus rare disease drug
FDA again delays review of Amicus rare disease drug
BioPharma Dive
Amicus Therapeutics
Pompe disease
China
FDA
AT-GAA
Flag link:
China rolls out first inhalable COVID vaccine
China rolls out first inhalable COVID vaccine
Reuters
China
vaccines
inhaled vaccines
COVID-19
Flag link:
China bans GSK from drug procurement activities through April 2024
China bans GSK from drug procurement activities through April 2024
Endpoints
China
GSK
Flag link:
Bayer, Hua Medicine snag first-in-class nod in China for Roche castoff diabetes drug
Bayer, Hua Medicine snag first-in-class nod in China for Roche castoff diabetes drug
Fierce Pharma
Hua Medicine
Bayer
Roche
China
diabetes
dorzagliatin
Flag link:

Pages